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Background. Staphylococcus aureus bacteremia is frequently
associated with metastatic complications and infective endocardi-
tis (IE). The Duke criteria for the diagnosis of IE utilize echo-
cardiographic techniques and are more sensitive than previous
criteria. The documentation of IE in patients undergoing hemo-
dialysis (HD) has become increasingly important in order to avoid
the overuse of empiric vancomycin and the emergence of antibi-
otic resistance.
Methods. Patients who developed S. aureus bacteremia while
undergoing HD at a tertiary medical center or one of four
affiliated outpatient HD units were identified. Clinical outcome
(death, metastatic complications, IE, and microbiologic recur-
rence) was assessed during hospitalization and at three months
after discharge. Transthoracic and transesophageal echocardio-
grams were performed and the Duke criteria were used to
diagnose IE. Pulse field gel electrophoresis was performed to
confirm genetic similarity of recurrent isolates.
Results. Four hundred and forty-five patients underwent hemo-
dialysis for 5431.8 patient-months. Sixty-two developed 65 epi-
sodes of S. aureus bacteremia (1.2 episodes/100 patient-months).
Complications occurred in 27 (44%) patients. Bacteremia re-
curred in patients who dialyzed through polytetrafluorethylene
grafts (44.4% vs. 7.1%, P 5 0.0.01), and there was a trend to
increased recurrence in patients who received only vancomycin
(19.5% vs. 7.1%, P 5 0.4). IE was diagnosed in 8 patients (12%),
six of whom had normal transthoracic echocardiograms.
Conclusions. Sensitive echocardiographic techniques and the
Duke criteria for the diagnosis of IE should be used to determine
the proper duration of antibiotic therapy in hemodialysis patients
with S. aureus bacteremia. This diagnostic approach, coupled with
early removal of hardware, may assist in improving outcomes.
Infection continues to be a major cause of morbidity and
mortality in hemodialysis patients. Bacteremia caused by
Staphylococcus aureus is frequent, and the portal of entry
involves prosthetic vascular access in approximately three-
fourths of cases [1–3]. Despite improvements in aseptic
technique and measures taken to decrease S. aureus car-
riage and colonization, S. aureus bacteremia remains a
serious and frequent complication of hemodialysis [4].
Staphylococcus aureus bacteremia is commonly associ-
ated with the development of metastatic complications
(osteomyelitis, abscess formation, septic arthritis), and in-
fective endocarditis (IE). The reported incidence of IE in
all patients with S. aureus bacteremia has varied from 0 to
64% [1, 5–19]. Since these studies were performed, the
transesophageal echocardiogram (TEE) has been shown to
increase the sensitivity of the detection of IE vegetations to
greater than 90% [12, 20, 21]. The Duke diagnostic criteria
for IE, which differ from previous criteria by utilizing
echocardiographic findings, are more sensitive and specific
than the previous Beth Israel criteria [22–24]. However, the
actual incidence of IE in hemodialysis patients has been
disputed because most case series have been small, retro-
spective, and the methods used to diagnose IE lacked
sensitivity.
The ease of weekly dosing and low incidence of associ-
ated toxicities has made vancomycin the most attractive
drug for the treatment of S. aureus bacteremia in hemodi-
alysis patients [25]. The empiric administration of long
courses (.1 month) of weekly vancomycin is common
practice in patients in whom the diagnosis of IE is sus-
pected but not confirmed. With the appearance of vanco-
mycin-resistant organisms in hemodialysis units, this use of
vancomycin has been discouraged [26, 27]. In addition,
several authors have suggested that vancomycin alone for
the treatment of IE is associated with suboptimal clinical
outcomes and slower in vitro killing rates when compared
with b-lactam antibiotics [28]. Thus, establishing the diag-
nosis of IE has become necessary in order to determine the
proper drug and duration of therapy in hemodialysis pa-
tients with S. aureus bacteremia.
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We conducted a prospective study of hemodialysis pa-
tients at Duke University Medical Center (DUMC) to
determine the incidence and outcome of S. aureus bacte-
remia, using transesophageal echocardiogram and the
Duke criteria for the diagnosis of endocarditis.
METHODS
All adult patients (.18 years old) undergoing hemodial-
ysis who had S. aureus bacteremia at DUMC between 15
September 1994 and 15 March 1996 were enrolled in this
prospective observational study. All patients were under-
going hemodialysis for chronic renal failure at DUMC or
one of four affiliated hemodialysis units. Patients were
excluded from analysis if they had polymicrobial bactere-
mia, or if they were neutropenic (,1.0 3 109 wbc/liter).
Patients with S. aureus bacteremia were identified by
daily communication between the microbiology laboratory
blood culture technician and one of the authors (K.M.,
V.F., A.G.). Demographic and clinical data (presence of
diabetes, immunocompromised status, type of vascular
access, organism sensitivity, and treatment) were recorded
for each patient with S. aureus bacteremia. In addition,
each patients’ clinical course and outcome (recurrent bac-
teremia, death, metastatic complication) were assessed
during treatment and three months after treatment. Pa-
tients with S. aureus bacteremia had repeat blood cultures
taken two days after initial recognition of bacteremia, and
thereafter when clinically indicated. Standard microbiolog-
ical methods were used for blood culture and sensitivity
studies. We recommended that transthoracic echocardio-
grams (TTEs) and transesophageal echocardiograms
(TEEs) be performed on all patients five to seven days after
the first positive blood culture. This advice was followed for
49 (79%) and 36 (58%) of 62 patients, respectively.
Clinical care of each patient, including antibiotic type
and duration was determined by each patient’s attending
physician. Vancomycin (20 mg/kg) and b-lactamase resis-
tant penicillins were dose-adjusted for underlying renal
failure in all patients. Oral rifampin was recommended in
conjunction with vancomycin, but this therapy was used at
the discretion of the attending nephrologist. In addition,
the necessity for surgical removal of an infected graft or
catheter, and the need for echocardiographic evaluation
was determined by the patient’s attending nephrologist.
We defined bacteremia as growth of S. aureus in two
blood cultures taken from peripheral sites, or from at least
one culture drawn from a central line in patients who had
fever (T . 38°C). Portal of entry was defined as skin if
history and physical examination provided evidence of soft
tissue infection or wound infection that did not involve the
vascular access. Patients who did not have an apparent
source of infection after history and physical examination
were considered to have vascular access-related bactere-
mia. Bacteremia was considered to be outpatient dialysis-
related if the culture result was obtained within two days of
admission. Recurrent bacteremia was defined as growth of
the same organism from cultures taken after one or more
negative cultures had been obtained. Infective endocarditis
was defined using the Duke diagnostic “major” (typical
blood culture and positive echocardiogram) and “minor”
(predisposition, fever, vascular phenomena, immunologic
phenomena, suggestive echocardiogram, and suggestive
microbiologic findings) criteria. Patients who had two ma-
jor criteria (S. aureus bacteremia and echocardiographic
findings consistent with IE), or one major criteria and three
minor criteria, or five minor criteria were diagnosed with IE
[22].
Pulse field gel electrophoresis (PFGE) was performed on
recurrent isolates in order to confirm genetic similarity, as
described by Kong et al [28]. Briefly, single isolates grown
overnight at 37°C in broth medium were embedded into
small agarose plugs, digested with lysotaphin and lysozyme,
and deproteinized using a reagent kit (GenePath I; Biorad,
Hercules, CA, USA). Restriction enzyme digestions with
SmaI were electrophoresed on 1% agarose gels, stained
with ethidium bromide, and interpreted according to pub-
lished guidelines [29].
SAS statistical software (SAS Institute, Inc., Cary, NC,
USA) was used for analysis of data. The outcome variables
were recurrence of bacteremia, metastatic complications,
and death. The association of demographic, clinical, micro-
biological and treatment variables with these outcomes was
assessed using two-sample t-tests, chi-squared analysis, and
Cochran-Mantel-Haenszel statistics.
RESULTS
From September 1994 to March 1996, 445 patients
underwent hemodialysis for a total of 5431.8 patient-
months. Sixty-two of these patients developed 65 episodes
of SAB, accounting for an incidence of 1.2 episodes per 100
patient-months. Thirty-nine (63%) patients were female,
and 46 (74%) patients were African-American. The mean
age was 53.5 years (range 25 to 87 years). Twenty-six (42%)
patients had diabetes mellitus, 6 (10%) had ongoing in-
jecting drug use, 4 (6%) chronically used oral steroids, and
2 (3%) were infected with human immunodeficiency virus
(HIV).
Fifty-eight (89%) episodes of bacteremia were consid-
ered to have originated in a vascular access device, and 7
(11%) episodes were associated with a concurrent soft
tissue infection. Thirty-one (53%) patients with device
related bacteremia were dialyzed through dual lumen,
tunneled, cuffed catheters, 8 (14%) were dialyzed through
temporary catheters, 10 (17%) were dialyzed through arte-
riovenous (AV) fistulas, and 9 (16%) were dialyzed through
polytetrafluoroethylene (PTFE) grafts. Forty-six (71%) ep-
isodes were acquired in the outpatient dialysis center and
19 (29%) were acquired in the hospital. Most patients
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received antibiotics within two days of the development of
fever. The mean duration from the onset of symptoms to
the receipt of intravenous antibiotics was 1.5 6 1.1 day
(range 1 to 8 days).
Methicillin-sensitive S. aureus (MSSA) was the cause of
bacteremia in 49 (75%) episodes and methicillin-resistant
S. aureus (MRSA) was the cause in 16 (25%). Forty
episodes (61%) were treated with intravenous vancomycin
alone. An additional 13 (20%) episodes were treated with
a combination of intravenous vancomycin and oral ri-
fampin. Only 12 (19%) episodes were treated with a
b-lactamase-resistant penicillin. Antibiotics were adminis-
tered for a mean duration of 31 6 14 days (range 7 to 90
days). Forty-eight patients (83% of patients with device-
related bacteremia) had their vascular access removed at a
mean of 11.6 6 24.6 days after presentation (range 1 to 120
days).
Complications of S. aureus bacteremia developed in 27
(44%) patients (Table 1). As shown in the Table, infective
endocarditis [8], osteomyelitis [8], and septic arthritis [4]
were the most common metastatic complications. No pa-
tient characteristics (age, diabetes mellitus, immunosup-
pressed status, type of vascular access), bacteremia charac-
teristics (organism sensitivity, portal of acquisition), or
treatment parameters (type or duration of antibiotics, time
to antibiotics or line removal) led to an increased risk for
the development of complications.
The detection of IE was particularly difficult. Clinical
characteristics such as the presence of a cardiac murmur or
known predisposing valvular heart disease were not predic-
tive of the development of IE (P 5 0.38 and 0.5, respec-
tively) and embolic phenomenon were rarely noted on
physical examination. Transthoracic echocardiograms were
performed on 49 (79%) patients who developed S. aureus
bacteremia, and transesophageal echocardiograms were
performed on 36 (55%) patients. Ten patients with normal
findings on TTE did not subsequently undergo a TEE
study. Results of both studies are shown in Figure 1. TEE
was performed in 28 patients who had normal findings
using TTE. Eight of these 28 patients (29%) had abnor-
malities detected by TEE that were not visualized by TTE.
Two of the eight (25%) patients had anatomic abnormali-
ties, and six (75%) patients had valvular vegetations. Thus,
TEE was required for diagnosis of six of the eight patients
with IE.
Bacteremia caused by a S. aureus with the same antibiotic
sensitivity pattern recurred in 10 (15%) patients. Of the 10
pairs of isolates, nine pairs had identical banding patterns
by PFGE analysis (data not shown), confirming a recur-
rence rate of 14%. Eight bacteremias recurred within one
month of antibiotic therapy, and one bacteremia recurred
within two months of antibiotic completion. Recurrent
bacteremia developed more often in patients who were
dialyzed through PTFE grafts compared to other forms of
vascular access (44.4% vs. 7.1%, Table 2). More patients
treated with vancomycin alone had recurrence of bactere-
mia when compared to patients treated with either b-lac-
tamase-resistant penicillins or combination regimens
(19.5% vs. 7.1%), even after controlling for the presence of
a PTFE graft (21.4% vs. 5.5%), however, the difference was
not statistically significant (Table 2).
Nine patients (14.5%) died as a consequence of infec-
tion. Eight patients died within one month of their bacte-
remia, and one patient died after the development of a
cardiac valvular ring abscess within two months of presen-
tation. Two of the patients that died had IE that was
detected only by TEE.
Fig. 1. Findings of transthoracic (TTE) and transesophageal (TEE)
echocardiograms in 62 patients with S. aureus bacteremia. Symbols are:
(f) valvular vegetations; (u) anatomic abnormalities; (n) normal findings;
(M) no study performed.
Table 1. Serious systemic complications in hemodialysis patients with
Staphylococcus aureus bacteremia (SAB; N 5 65 episodes)
Complication
# Patients %
episodes SAB
Osteomyelitis 7 (11%)
Septic joint 2 (3%)
Epidural abscess 2 (3%)
Infective endocarditis 1 (2%)
Multifocal infection 8 (13%)
Infective endocarditis with:
septic arthritis 2
line vegetation 3
osteomyelitis 1
meningitis 1
soft tissue abscess 1
Death 9 (14%)
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DISCUSSION
Staphylococcus aureus is the most common cause of
bacteremia in hemodialysis patients [1–3]. In this prospec-
tive study, we used aggressive diagnostic methods and
follow-up to demonstrate a surprisingly large incidence of
metastatic complications (44%) and death (14%) in dialysis
patients who develop bacteremia with S. aureus. Echocar-
diographic techniques, combined with the sensitive Duke
Criteria for the diagnosis of IE, have enabled us to docu-
ment that infective endocarditis occurs more frequently
(14%) than previously described. S. aureus bacteremia
recurs more frequently in patients who are dialyzed
through PTFE grafts, and there is a trend to increased
recurrence in patients who receive vancomycin as their only
antibiotic.
Our population of hemodialysis patients had an inci-
dence of S. aureus bacteremia (1.2 per 100 patient-months)
that is consistent with previous results approximating 0.1
per patient-year [30]. In a recent literature review, Raad
and Sabbagh concluded that serious complications of cath-
eter-related S. aureus bacteremia occur at a frequency of
20% to 30% in the general population [9]. The authors of
a prior retrospective study of S. aureus bacteremia in 30
hemodialysis patients suggested that the incidence of seri-
ous infectious complications in hemodialysis patients
(27%) did not differ from the rate of complications in
nonuremic patients [6]. The high incidence of noncardiac
metastatic complications (17%) and recurrent bacteremia
(14%) that we observed in our study confirms the results of
these prior retrospective reports.
Documenting the diagnosis of IE has become important
in order to avoid the overuse of long durations of empiric
vancomycin in this patient population. The actual incidence
of IE in patients with S. aureus bacteremia has been
disputed, with rates ranging from 4% to 64% in the
literature [8–19]. In a retrospective study of hemodialysis
patients, Quarles, Rutsky and Rostand reported an inci-
dence of IE of only 6.3% [1], and Francioli and Masur
reported a similar incidence of 5.4% [6]. Both groups
noted, however, that their findings might have been under-
estimated due to a lack of sensitivity of their diagnostic
criteria for IE. Since those studies were performed, the
Duke Criteria for the diagnosis of IE, which utilize echo-
cardiographic findings, have been validated pathologically
and found to be more sensitive and specific than previous
criteria that rely on physical examination and laboratory
results [23, 24]. In this study, the use of more sensitive
diagnostic techniques allowed us to detect a two- to three-
fold increase (14% vs. 5 to 6%) in IE than found in
previous studies. Since only 55% of our patients underwent
TEE, the true incidence of IE may have been even higher.
This high incidence of previously undetected IE may
explain the high relapse rate in patients treated with short
courses of antibiotic therapy [31].
Transesophageal echocardiogram appears to be more
sensitive than TTE in detecting vegetations early (5 to 7
days) after bacteremia, as TTE detected only 25% of
vegetations subsequently detected by TEE. This observa-
tion, which is consistent with our previous published find-
ings [32], may be explained by enhanced visualization of
“small” vegetations. However, since the present study was
not designed to compare the two tests, further investiga-
tions are warranted to determine the sensitivity and speci-
ficity of these echocardiographic techniques performed
early after bacteremia.
It is also important to note that history and clinical
findings were of limited value as indicators of the presence
or absence of IE, as we did not find that the presence of a
murmur or history of pre-existing valvular disease at the
time of first bacteremia were reliable predictors for the
development of IE. Although evidence suggests that com-
munity-acquired S. aureus bacteremia results in an in-
creased risk of IE when compared to nosocomial bactere-
mia [19], mode of acquisition is particularly difficult to
assess in these patients who undergo hemodialysis several
times a week in a hospital setting. In addition, the previ-
ously reported observations that patients with identifiable
or removable portals of infection, and intravenous drug
Table 2. Risk factors (patient factor or treatment variable) for bacteremia recurrence (N 5 65 episodes)
Patient factor
Number of
patients
Risk of recurrent bacteremia
95% CI P valuea
Patients with
recurrence (%)
Relative
risk
Dialysis through PTFE graft
yes 9 4 (44.4%) 6.22 1.9 to 20.5 (0.01)
no 56 4 (7.1%)
Treatment with vancomycin only
yes 41 8 (19.5%) 2.73 0.4 to 20 (0.4)
no 14 1 (7.1%)
Treatment with vancomycin,
controlled for PTFE graft
yes 28 6 (21.4%) 1.29 0.2 to 8.8 (0.2)
no 18 1 (5.5%)
a Fisher’s exact 2-tailed P value reported
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users have more favorable prognosis were not supported by
our findings [1, 12].
Our patients had a 44% complication rate and a 14%
relapse rate despite the initiation of antimicrobial therapy
within two days of the onset of symptoms. We found that
patients who were dialyzed through PTFE grafts have a
sixfold increased risk of bacteremia recurrence. This obser-
vation may be explained by the fact that it is difficult to
completely remove PTFE grafts. Thus, the possibility exists
that relapse is due to a persistent focus of infection
remaining after partial resection. Another possibility for
the high rate of relapse and complications is the frequent
use of vancomycin as a sole antibiotic, a regimen that may
be less effective than that including combinations of anti-
biotics or b-lactamase-resistant penicillins [19]. In this
study, more patients treated with vancomycin (20%), had
recurrence of bacteremia than patients who were treated
with b-lactamase-resistant penicillins or combinations of
antibiotics (7%). Although our sample size was not large
enough to allow for statistical significance (CI 0.4 to 20), it
is likely that patients with more severe infections would
receive b-lactamase-resistant penicillins or combinations of
antibiotics, biasing the results in the opposite direction.
Though in the present study this trend may be explained by
levels of vancomycin waning at the end of dosing intervals,
several previous studies have documented similar subopti-
mal outcomes in vancomycin-treated patients despite ade-
quate drug levels and susceptible strains [19]. This issue
needs to be addressed in a larger prospective randomized
trial.
Our study is limited by its observational design and
relatively small sample size, which may have obscured small
differences in patient groups predicting outcome. Also, not
all patients were evaluated by echocardiogram, possibly
resulting in an underestimated incidence of IE. Finally, we
have no data on nasal carriage of S. aureus in our patients,
which has been reported to result in an increased risk of
infection in patients undergoing dialysis [30, 33].
Nearly half of our patients (44%) developed serious
systemic complications, including osteomyelitis, infective
endocarditis, and death following a bacteremia caused by S.
aureus. By using sensitive diagnostic criteria for IE, we have
documented a 14% incidence of IE in this setting, possibly
explaining the frequent recurrence of bacteremia after
short courses of antibiotic therapy. In light of the recent
emergence of vancomycin-resistant S. aureus in patients
with extensive exposure to vancomycin [27], we believe that
hemodialysis patients with S. aureus bacteremia should
undergo sensitive echocardiographic examination in order
to determine the proper duration of antibiotic treatment
instead of receiving long courses of empiric therapy. In
addition, the trend of recurrent bacteremia associated with
the use of vancomycin emphasizes the need for future
prospective studies to evaluate the efficacy of other antibi-
otics in this setting. Suboptimal outcomes, combined with
the recent emergence of resistance, emphasize that vanco-
mycin should never be used simply for convenience of
administration when other antibiotics are an option. Fi-
nally, the aggressive and complete removal of infected
intravascular devices in patients with S. aureus bacteremia
should be strongly considered in order to prevent meta-
static and recurrent infection.
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APPENDIX
Abbreviations used in this article are: AV, arteriovenous; HD, hemo-
dialysis; HIV, human immunodeficiency virus; IE, infective endocarditis;
PFGE, pulse field gel electrophoresis; PTFE, polytetrafluoroethylene;
MRSA, methicillin-resistant S. aureus; MSSA, methicillin-sensitive S.
aureus; S. aureus, Staphylococcus aureus; TEE, transesophageal echocar-
diograms; TTE, transthoracic echocardiogram; wbc, white blood cells.
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